Six ETFs sold $10.5 million of Pacira BioSciences stock in Thursday's session.
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
Detailed price information for Viatris Inc (VTRS-Q) from The Globe and Mail including charting and trades.
Viatris is acquiring Pacira Biosciences to boost its pain management portfolio and address revenue stagnation. Read why VTRS stock is upgraded to a hold.
Pacira BioSciences (PCRX) stock surged 44% after Viatris’ $36.50/share buyout deal.
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose 34.2% to
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.
The specialty pharmaceutical company is being acquired.
Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
This is the newest page. Registered accounts read further back.